Loading patent…
AssigneeMacfarlane Burnet Institute for Medical Research and Public Health Limited
InventorsPhillip Mark HOGARTH, Bruce David WINES
Estimating the term…
An immunotherapeutic protein and methods of use and production thereof are disclosed, wherein the immunotherapeutic protein comprises one or more immunoglobulin heavy chain polypeptide comprising an Fc region component comprising at least a constant heavy chain domain 3 (CH3) domain (or at least a constant heavy domain 4 (CH4) domain), wherein said one or more polypeptide includes an amino acid substitution at a position corresponding to H429 of the amino acid sequence of human IgG1 heavy chain (Eu numbering) such as H429Y and H429F. The immunotherapeutic protein may be in the form of, for example, an antibody, antibody-like molecule or fusion protein. The amino acid substitution may have the effect of enabling the immunotherapeutic protein to oligomerise (eg into a hexameric form) either in solution or upon binding to a relevant target.
An immunotherapeutic protein comprising one or more immunoglobulin heavy chain polypeptide comprising an Fc region component comprising at least a constant heavy chain domain 3 (CH3) domain (or at least a constant heavy domain 4 (CH4) domain), wherein said one or more polypeptide includes an amino acid substitution at a position corresponding to H429 of the amino acid sequence of human IgG1 heavy chain (Eu numbering).
The immunotherapeutic protein of claim 28, wherein the immunotherapeutic protein forms a hexamer upon binding to a relevant target through “on target” oligomerisation.
The immunotherapeutic protein of claim 28, wherein the amino acid substitution at the position corresponding to H429 of the amino acid sequence of the human IgG1 heavy chain polypeptide is an H→F substitution.
The immunotherapeutic protein of claim 28, wherein the amino acid substitution at the position corresponding to H429 of the amino acid sequence of the human IgG2 heavy chain polypeptide is an H→F substitution.
The immunotherapeutic protein of claim 28, wherein the amino acid substitution at the position corresponding to H429 of the amino acid sequence of the human IgG3 heavy chain polypeptide is an H→F substitution.
Dependencies are inferred from the claim text.